X4 is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4’s pipeline is comprised of a first-in-class, oral, small molecule antagonist of chemokine receptor CXCR4, which has the potential to treat a broad range of rare diseases resulting from dysfunction of the CXCR4 receptor pathway, including primary immunodeficiencies, neutropenia, and certain cancers.
X4 Pharmaceuticals, Inc. is a global, late-stage clinical biopharmaceutical company. X4 is a leader in the discovery and development of novel therapies for the treatment of rare diseases of the immune system, including WHIM syndrome and chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts with a research center of excellence in Vienna, Austria